Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity

Nancy L. Reinsmoen, Arthur J. Matas

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Previous studies suggest stable renal transplant recipients can have either prednisone (P) or cyclosporine withdrawn; however, 30% of these patients undergo rejection requiring reinstitution of P or CsA. Some patients return to baseline creatinine levels, while others either stabilize at a higher creatinine level or lose their graft. It would be ideal to establish immunologically based criteria for selecting patients who can be successfully withdrawn or tapered from immunosuppression. We have investigated the development of donor antigen-specific hyporeactivity by using donor cells and/or homozygous typing cells defining the HLA-Dw specificities of the donor cells as stimulator cells in the mixed lymphocyte culture (MLC) and comparing the pre-and posttransplant responses of peripheral blood mononuclear cells from 199 kidney transplant recipients. Of these, 27% of the haploidentical living-related donor and 25% of the cadaver recipients developed in vitro donor antigen-specific hyporeactivity. The LRD recipients who did so have lower mean creatinine levels at 6, 12, and 24 months posttransplant (1.3, 1.3, and 1.2, respectively) than those who remained responsive to the donor antigens (1.6, 1.7, and 1.8) (P<0.05). However, no differences in the mean creatinine levels were observed between CAD recipients who developed donor antigen-specific hyporeactivity and those who remained responsive. Rejection episodes were common in all groups in the first 3 months posttransplant; however, recipients who developed donor antigen-specific hypo-reactivity tended to experience fewer rejection episoDR MM) groups. Donor antigen-specific hyporeactivity could not be determined (UND) for 30 of the LRD recipients and 33 of the CAD recipients due to lack of mismatching for DR antigens (0.03 DR MM and 0.25 DR MM, respectively). Although these groups of recipients were well matched for HLA-DR antigens, the number of late rejection episodes, incidence of chronic rejection, mean creatinine values, and graft survival were comparable to those who remained reactive to the donor disparate antigens. We conclude that immune regulation-as evidenced by the development of donor antigen-specific hyporeactivity-correlates with improved graft outcome and may permit lower immunosuppression.

Original languageEnglish (US)
Pages (from-to)1017-1023
Number of pages7
Issue number5
StatePublished - May 1993


Dive into the research topics of 'Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity'. Together they form a unique fingerprint.

Cite this